Abstract
Transforming growth factor-β (TGF-β) is a potent regulator of numerous processes including hematopoiesis, cell proliferation, differentiation and activation. TGF-β has pleiotropic and profound effects on the immune system and on hematologic malignancies, ie leukemia. It is the most potent immunosuppressor described to date. Evidence exists that the immunosuppressive potential of TGF-β is an important promoter of malignant cell growth. This is partly caused by TGF-β-induced interference with the generation of tumor-specific cytotoxic T lymphocytes, but also by TGF-β-induced promotion of angiogenesis and tumor stroma formation. Until now, significant clinical responses have not been achieved with the current cancer immunotherapeutic approaches. One of the possible explanations for this failure is immunosuppression induced by tumor-derived TGF-β. Here, several strategies to counteract the immunosuppressive effects of TGF-β and the current limitations of these strategies will be discussed. Knowledge of the mechanisms by which TGF-β interferes with the development of an anti-tumor response and of the strategies to counteract these immunosuppressive activities is crucial to improve the current cancer immunotherapeutic approaches.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
de Visser, K., Kast, W. Effects of TGF-β on the immune system: implications for cancer immunotherapy. Leukemia 13, 1188–1199 (1999). https://doi.org/10.1038/sj.leu.2401477
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401477
Keywords
This article is cited by
-
Spatiotemporal dynamics of a glioma immune interaction model
Scientific Reports (2021)
-
Tumor cell secretion of soluble factor(s) for specific immunosuppression
Scientific Reports (2015)
-
Disturbed Th17/Treg Balance in Patients with Non-small Cell Lung Cancer
Inflammation (2015)
-
Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors
Molecular Therapy - Methods & Clinical Development (2014)
-
The association between CD4+ CD25+ regulatory T cells and non-small cell lung carcinoma
Comparative Clinical Pathology (2014)